سامية محمد مصطفى



شبكة المعلومات الحامعية

بسم الله الرحمن الرحيم



-Caro-

سامية محمد مصطفي



شبكة العلومات الحامعية



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم





سامية محمد مصطفى

شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسو

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة يعيدا عن الغيار



سامية محمد مصطفي



شبكة المعلومات الجامعية



المسلمة عين شعور المسلمة عين شعور المسلمة عين شعور المسلمة عين شعور المسلمة ا

سامية محمد مصطفى

شبكة المعلومات الحامعية



بالرسالة صفحات لم ترد بالأصل



HCV Recurrence Following Living Donor Liver Transplantation In Egyptian Adults

Thesis
Submitted for the Fulfillment of
Master degree in Tropical Medicine

By

Tamer Ismail Magdi Gouda (M.B, B.Ch)

Under the supervision of

Dr.Mahasen Abdel-Rahman

Professor of Tropical Medicine Faculty of Medicine Cairo university

Dr.Ayman Yosry Abdel-Rahim/

Professor of Tropical Medicine
Faculty of Medicine
Cairo university

Dr. Ahmed el-Taweel

Professor of Pathology Faculty of Medicine Ain shams University

Cairo University 2006

12751

محضر
اجتماع لجنة الحكم على الرسنالة المقدمة من
الطبيب / كامر اسما يمل مدى عود ه
توطنة للحصول على درجة الماجستير /الدعتوراه
فی ہے لیا ہے ا
park, prop. and dark core and grad core. and order total made code code code office.
تحت عنوان: باللغة الانجليزية: HCV Necurrena Following
HCV Recurrence Following : Lluing Donor Liver Transplantation in Egyptian
a.a.u.i.s.
: باللغة العربية : عود ١٥ التهاب الكيد الغير مين (جين) دعد
: باللغة العربية : عود 10 التهاب الكدر الغير سي (١٠٠٠) دعد زراعه الكيد من متبرع من ي المكريس المالغين
- '
بناء على موافقة الجامعة بتاريخ ٦٠/ > / ٢٠٠٦ تم تشكيل لجنة الفحص والمناقشة للرسالة المذكورة أعلاد على النحو التالى :-
للرسالة المذكورة اعلاد على النحو التالي :-
المدامي المستورة المان المرام المرام المرام المرام المسرون المشرفين
٢. د أسر ف عمر عد لمرار من من من من من داخلي
٣. اد يه ٢٠٠١ عد بلاء آت من سنات كلي سعور بلا والمدين معتدن خارجي
بعد فحص الرسالة بواسطة كل عضو منفردا وكتابة تقارير منفردة نكل منهم انعقدت اللجنة
مجتمعة في يوم ١٠٠٠ ليكونا ٨ بناريخ ١٠١ > ٢٠٠٦ بقسم مدرج من المجتلف مرع
بكلية الطب - جامعة القاهرة وذلك لمناقشة الطالب في جلسة علنية في موضوع الرسالة والندّانج
التي توصل اليها وكذلك الأسس العلمية التي قام عليها البحث .
قرار اللجنة:
2) L J J - L J - L
-
توقيعات أعضاء اللجنة :-
المشرف الممتحن الممتحن الداخلي الممتحن الخارجي
!

بسم الله الرحمن الرحيم

" يرفع الله الذين آمنو امنكم و الذين أوتوا العلم درجات "

سورة المجادلة - أية 11

ACKNOWLEDGEMENT

I would like to thank **ALLAH** alot for the kindness, patience and strength he gave to me to achieve this work and made me able to finish it.

I am greatly honored to express my deep gratitude and faithfulness to **Dr. Mahasen Abdel-Rahman**, professor of Tropical Medicine, Cairo University. She gave me much of her time, experience, kindness, sympathy, generous help and valuable advices that cannot be expressed in words. Her motherhood attitude and encouragement were so supportive for the completion of this work.

I am extremely grateful and bound to honor to **Dr. Ayman Yosry Abdel-Rahim**, professor of Tropical Medicine, Cairo University, who gave me valuable advices, support and sincere encouragement. His valuable efforts, comments and collaboration were the causes to complete this work properly.

I also thank **Dr. Ahmed Abdel-Halem el-Taweel** professor of pathology, Ain Shams University, who was of great help for this study.

I also extend my deep thanks and appreciations to Professor **Dr**. **Serag Zakaria**, Professor of Tropical Medicine and the head of Tropical Medicine Department, Cairo University for his continuous support and encouragement.

I also thank all the Staff members of the Tropical Medicine Department, By whom all, I was very much impressed by the noble characters, generous attitude and kind sympathy. I would like to express my deepest gratitude and profound appreciation to **Dr. Naglaa Zayed**, lecturer of Tropical Medicine, Cairo University, for her kindness, goodness and her valuable faithful advices throughout the work.

Words are short of expressing my deepest appreciation to **Dr**.

Wafaa El-Akel and to all my colleague of Tropical Medicine Department,

Cairo University, for their great support, help, and understanding.

I would like to express my deep gratitude and respect to my beloved family for their strong support throughout the work wishing them all the happiness and good health. They were always pushing me forwards to achieve the work and were always rising my spirit.

I would like to show my appreciation to the members **Dar EL-**Found Hospital particularly the transplantation team for their support and guidness.

Last but not least to all the patients who suffer a lot, I hope that with this work and other studies we can share in alleviating their suffering.

ABSTRACT:

<u>Background:</u> HCV related end stage liver disease is the main indication for living donor liver transplantation in Egypt. Many risk factors may contribute to the HCV recurrence post LDLT. Our aim was to investigate the incidence of clinical HCV recurrence post-LDLT in adult Egyptian patients and to evaluate disease progression in these patients and its impact on outcome of liver transplantation.

Patients and methods: This study was conducted on 98 cases of adult to adult LDLT in Dar El Fouad hospital. All of the recipients received a right lobe donation, only two received left lobe donation. Our inclusion criteria for clinical HCV recurrence were: elevated transaminases; seropositivety of HCV PCR; and confirmatory histology. They were clinically assessed and investigated (Laboratory including: Full blood picture, coagulation profile, C-reactive protein, Liver function tests, Kidney function tests, Immunosuppresant level and Imaging by Abdominal Ultrasound, Abdominal Doppler of the portal vein, hepatic arteries and veins daily follow up during hospital stay and on weekly basis during the first three months then on monthly basis till the end of six months and then every two month.

Results: Recurrence of HCV was universal in terms of viremia. Clinical recurrence of HCV was seen in 31.1% of recipients and no mortality was reported among them. Clinically recurrent HCV was mild. There was a significant impact of the previous exposure to hepatitis B virus on the development of clinical HCV recurrence while other recipient factors (age, sex, child's score, MELD score and seropositivity for CMV) did not influence HCV recurrence. It was noticed that HCV pre transplant viral titre was higher in HCV recurrent group yet it was not statistically significant. Other risk factors as donor age, donor sex, immunosuppressive drugs, GRWR and estimated graft size did not affect HCV recurrence.

<u>Conclusion:</u> HCV is the main indication for LDLT in Egypt. Although clinical HCV recurred in about 31% of patients yet no mortality was reported in this group. There are many risk factors affecting HCV recurrence yet only the previous exposure to HBV had significantly influenced HCV recurrence in our study.

Keywords: Recurrent HCV, living donor liver transplantation, Egyptian adults.




TABLE OF CONTENTS	
Introduction	,
- Introduction	$\frac{1}{2}$
- Living Donor Liver Transplantation	3
- Donor selection	7
- Graft selection	8
- Recipient selection	10
Aim of work	13
Natural history of recurrence	, ,
- Timing of infection	14
- Post transplant HCV kinetics	15
- Progression of disease	17
- Biochemical and histological patterns of hepatitis C virus recurrence	20
 Biomarkers used to predict recurrent disease in hepatitis C transplant patients 	24
- Recurrent hepatitis C virus infection versus acute cellular	25
rejection	
Factors associated with histologic severity of recurrence	27
- Factors associated with histologic severity of recurrence	29
- Viral factors	30
- Recipient factors	$\begin{vmatrix} 30 \\ 31 \end{vmatrix}$
- Donor factors	32
- Graft factors	35
- Immunosuppression	39
- HLA matching	40
- CMV	70
Treatment of recurrent hepatitis C virus infection	41
- Pre-transplantation therapy	41
- Peri-operative therapy	43
- Post-transplantation therapy	44
- Pre-emptive therapy	
- Treatment of established disease	46
- Re-transplantation	51
Patients and Methods	55
Results	67
Discussion	97
Summary and Conclusion	111

Recommendations	113
References	114

LIST OF TABLES

Table (II): Table (III): Table (III): Table (III): Table (III): Table (III): Table (IV): Table		
Table (II): Indications of liver transplantation in chronic liver disease the histologic features of recurrent hepatitis C infection versus acute cellular rejection Table (V): Factors associated with increased severity of recurrent hepatitis C infection Table (VI): Factors affecting recurrent hepatitis C in LDLT recipients UNOS Status Table (VIII): Child-Turcotte-Pugh score Table (I): Demographic characteristics of the recipient Demographic characteristics of the Donor Table (3): HCV recurrence in the relation to the recipient sex Table (3): HCV recurrence in the relation to the recipient age HCV recurrence in relation to the MELD score Table (6): HCV recurrence in relation to the MELD score Table (8): HCV recurrence in relation to Child's score Table (9): HCV recurrence in relation to CMV IgG Table (10): HCV recurrence in relation to Dre transplant viremia titre Table (13): HCV recurrence in relation to pre transplant viremia level Table (13): HCV recurrence in relation to pre transplant viremia level Table (14): HCV recurrence in relation to pre transplant viremia level Table (15): Relation between HCV recurrence and HBc Ab total HCV recurrence in relation to tacrolimus Table (16): HCV recurrence in relation to tacrolimus HCV recurrence in relation to tacrolimus Table (17): HCV recurrence in relation to tacrolimus Table (18): HCV recurrence in relation to tacrolimus Table (19): HCV recurrence in relation to to tacrolimus Table (20): HCV recurrence in relation to donor sex Table (21): HCV recurrence in relation to donor sex Table (22): Type of donor graft in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Relation between estimated graft weight(g) and HCV recurrence Relation between estimated graft weight(g) and HCV recurrence in relation to recipient total hospital stay HCV recurrence in relation to recipient total hospital stay HCV recurrence in relation to recipient total hospital stay HCV recurrence in relation to recipient total hospita	Table (I):	
Table (II): Indications of liver transplantation in chronic liver disease the histologic features of recurrent hepatitis C infection versus acute cellular rejection Table (V): Factors associated with increased severity of recurrent hepatitis C infection Table (VI): Factors affecting recurrent hepatitis C in LDLT recipients UNOS Status Table (VIII): Child-Turcotte-Pugh score Table (I): Demographic characteristics of the recipient Demographic characteristics of the Donor Table (3): HCV recurrence in the relation to the recipient sex Table (3): HCV recurrence in the relation to the recipient age HCV recurrence in relation to the MELD score Table (6): HCV recurrence in relation to the MELD score Table (8): HCV recurrence in relation to Child's score Table (9): HCV recurrence in relation to CMV IgG Table (10): HCV recurrence in relation to Dre transplant viremia titre Table (13): HCV recurrence in relation to pre transplant viremia level Table (13): HCV recurrence in relation to pre transplant viremia level Table (14): HCV recurrence in relation to pre transplant viremia level Table (15): Relation between HCV recurrence and HBc Ab total HCV recurrence in relation to tacrolimus Table (16): HCV recurrence in relation to tacrolimus HCV recurrence in relation to tacrolimus Table (17): HCV recurrence in relation to tacrolimus Table (18): HCV recurrence in relation to tacrolimus Table (19): HCV recurrence in relation to to tacrolimus Table (20): HCV recurrence in relation to donor sex Table (21): HCV recurrence in relation to donor sex Table (22): Type of donor graft in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Relation between estimated graft weight(g) and HCV recurrence Relation between estimated graft weight(g) and HCV recurrence in relation to recipient total hospital stay HCV recurrence in relation to recipient total hospital stay HCV recurrence in relation to recipient total hospital stay HCV recurrence in relation to recipient total hospita	Table (II):	Characteristics of living donor and cadaveric liver transplant recipients
the histologic features of recurrent hepatitis C infection versus acute cellular rejection Factors associated with increased severity of recurrent hepatitis C infection Table (VI): Factors affecting recurrent hepatitis C in LDLT recipients Table (VII): UNOS Status Table (VIII): Child-Turcotte-Pugh score Table (I): Demographic characteristics of the recipient Table (2): Demographic characteristics of the Donor Table (3): HCV recurrence (n=74) Table (3): HCV recurrence in the relation to the recipient age HCV recurrence in relation to the MELD score Table (3): HCV recurrence in relation to CMV IgG Table (9): HCV recurrence in relation to CMV IgG Table (10): HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to tacrolimus Table (13): Relation between in relation to tacrolimus toxicity HCV		Indications of liver transplantation in chronic liver disease
hepatitis C infection versus acute cellular rejection Table (V): Factors associated with increased severity of recurrent hepatitis C infection Table (VII): Factors affecting recurrent hepatitis C in LDLT recipients Table (VIII): UNOS Status Table (VIII): Child-Turcotte-Pugh score Table (I): Demographic characteristics of the recipient Demographic characteristics of the Donor Table (3): Demographic characteristics of the Donor Table (3): HCV recurrence in the relation to the recipient sex Table (3): HCV recurrence in relation to the MELD score Table (6): HCV recurrence in relation to the MELD score Table (6): HCV recurrence in relation to CMV IgG Table (9): HCV recurrence in relation to CMV IgG Table (10): HCV recurrence in relation to Demographic vicential titre Table (12): HCV recurrence in relation to pre transplant viremia level Table (13): HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to tacrolimus Table (13): Relation between HCV recurrence and HBc Ab total HCV recurrence in relation to tacrolimus Table (19): HCV recurrence in relation to tacrolimus Table (20): HCV recurrence in relation to donor age HCV recurrence in relation to donor age HCV recurrence in relation to donor sex Table (23): Relation between GRWR and HCV recurrence Relation between GRWR and HCV recurrence Relation between estimated graft weight(g) and HCV recurrence Relation between estimated graft weight(g) and HCV recurrence Table (26): HCV recurrence in relation to recipient total hospital stay HCV r		
Table (V): Factors associated with increased severity of recurrent hepatitis C infection Table (VII): Factors affecting recurrent hepatitis C in LDLT recipients Table (VIII): UNOS Status Table (IX): Modified HAI Grading: Necroinflammatory Scores Table (I): Demographic characteristics of the recipient Demographic characteristics of the Donor Table (3): HCV recurrence (n=74) Table (4): HCV recurrence in the relation to the recipient sex Table (5): HCV recurrence in relation to the MELD score Table (7): HCV recurrence in relation to the MELD score Table (9): HCV recurrence in relation to Child's score Table (10): HCV recurrence in relation to To CMV IgG Table (11): HCV recurrence in relation to pre transplant viremia titre Table (12): HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to be transplant viremia level HCV recurrence in relation to be transplant viremia level HCV recurrence in relation to be transplant viremia level HCV recurrence in relation to be transplant viremia level HCV recurrence in relation to be transplant viremia level HCV recurrence in relation to be transplant viremia level HCV recurrence in relation to to tacrolimus Table (13): Table (13): Relation between HCV recurrence and HBc Ab total HCV recurrence in relation to to tacrolimus Table (24): Type of donor graft in relation to donor sex Table (23): Table (24): Relation between GRWR (mean) and HCV recurrence Relation between estimated graft weig	(-)	-
infection Table (VI): Table (VII): Table (VIII): Table (VIII): Child-Turcotte-Pugh score Table (IX): Modified HAI Grading: Necroinflammatory Scores Table (IX): Demographic characteristics of the recipient Demographic characteristics of the Donor Table (3): HCV recurrence (n=74) Table (3): HCV recurrence in the relation to the recipient sex Table (5): HCV recurrence in relation to the MELD score Table (6): HCV recurrence in relation to the MELD score Table (8): HCV recurrence in relation to CMV IgG Table (10): HCV recurrence in relation to Dre transplant viremia titre Table (12): HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia titre Table (15): Relation between HCV recurrence and HBc Ab total HCV recurrence in relation to tacrolimus Table (18): HCV recurrence in relation to tacrolimus toxicity Table (29): HCV recurrence in relation to donor age HCV recurrence in relation to donor age HCV recurrence in relation to donor age Table (21): Table (23): Relation between GRWR (mean) and HCV recurrence Relation between GRWR and HCV recurrence Relation between estimated graft weight(g) and HCV recurrence Relation between estimated graft weight(g) and HCV recurrence Table (26): HCV recurrence in relation to INF+Ribavirin therapy Time at which HCV recurrence was diagnosed		
Table (VIII): UNOS Status Table (VIII): Child-Turcotte-Pugh score Table (1X): Modified HAI Grading: Necroinflammatory Scores Table (1): Demographic characteristics of the recipient Table (2): Demographic characteristics of the Donor Table (3): HCV recurrence (n=74) Table (4): HCV recurrence in the relation to the recipient sex Table (5): HCV recurrence in relation to the MELD score Table (6): HCV recurrence in relation to the MELD score Table (7): HCV recurrence in relation to Child's score Table (8): HCV recurrence in relation to CMV IgG Table (10): HCV recurrence in relation to Draw IgG Table (11): HCV recurrence in relation to pre transplant viremia titre Table (13): HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level Table (14): HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant wiremia level HCV recurrence in relation to tacrolimus Table (16): Relation between HCV recurrence and HBc Ab total HCV recurrence in relation to tacrolimus HCV recurrence in relation to tacrolimus HCV recurrence in relation to tacrolimus toxicity HCV recurrence in relation to donor age Table (20): HCV recurrence in relation to donor sex Type of donor graft in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Relation between GRWR and HCV recurrence Relation between GRWR and HCV recurrence Relation between estimated graft weight(g) and HCV recurrence Table (26): HCV recurrence in relation to INF+Ribavirin therapy Table (27): HCV recurrence in relation to INF+Ribavirin therapy Time at which HCV recurrence was diagnosed	Table (V):	
Table (VIII): UNOS Status Table (VIII): Child-Turcotte-Pugh score Table (1X): Modified HAI Grading: Necroinflammatory Scores Table (1): Demographic characteristics of the recipient Table (2): Demographic characteristics of the Donor Table (3): HCV recurrence (n=74) Table (4): HCV recurrence in the relation to the recipient sex Table (5): HCV recurrence in relation to the MELD score Table (6): HCV recurrence in relation to the MELD score Table (7): HCV recurrence in relation to Child's score Table (8): HCV recurrence in relation to CMV IgG Table (10): HCV recurrence in relation to Draw IgG Table (11): HCV recurrence in relation to pre transplant viremia titre Table (13): HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level Table (14): HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant wiremia level HCV recurrence in relation to tacrolimus Table (16): Relation between HCV recurrence and HBc Ab total HCV recurrence in relation to tacrolimus HCV recurrence in relation to tacrolimus HCV recurrence in relation to tacrolimus toxicity HCV recurrence in relation to donor age Table (20): HCV recurrence in relation to donor sex Type of donor graft in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Relation between GRWR and HCV recurrence Relation between GRWR and HCV recurrence Relation between estimated graft weight(g) and HCV recurrence Table (26): HCV recurrence in relation to INF+Ribavirin therapy Table (27): HCV recurrence in relation to INF+Ribavirin therapy Time at which HCV recurrence was diagnosed	Table (VI):	Factors affecting recurrent hepatitis C in LDLT recipients
Table (1X): Modified HAI Grading: Necroinflammatory Scores Table (1): Demographic characteristics of the recipient Table (2): Demographic characteristics of the Donor Table (3): HCV recurrence (n=74) Table (4): HCV recurrence in the relation to the recipient sex Table (5): HCV recurrence in the relation to recipient age Table (6): HCV recurrence in relation to the MELD score Table (7): HCV recurrence in relation to Child's score HCV recurrence in relation to CMV lgG Table (9): HCV recurrence in relation to CMV lgG Table (10): HCV recurrence in relation to Dre transplant viremia titre Table (12): HCV recurrence in relation to pre transplant viremia level Table (23): Type of donor graft in relation to recurrence Relation between GRWR and HCV recurrence Relation be		
Table (1X): Modified HAI Grading: Necroinflammatory Scores Table (1): Demographic characteristics of the recipient Table (2): Demographic characteristics of the Donor Table (3): HCV recurrence (n=74) Table (4): HCV recurrence in the relation to the recipient sex Table (5): HCV recurrence in the relation to recipient age Table (6): HCV recurrence in relation to the MELD score Table (7): HCV recurrence in relation to Child's score HCV recurrence in relation to CMV lgG Table (9): HCV recurrence in relation to CMV lgG Table (10): HCV recurrence in relation to Dre transplant viremia titre Table (12): HCV recurrence in relation to pre transplant viremia level Table (23): Type of donor graft in relation to recurrence Relation between GRWR and HCV recurrence Relation be	Table (VIII)	Child-Turcotte-Pugh score
Table (1): Demographic characteristics of the recipient Table (2): Demographic characteristics of the Donor Table (3): HCV recurrence (n=74) Table (4): HCV recurrence in the relation to the recipient sex Table (5): HCV recurrence in the relation to recipient age Table (6): HCV recurrence in relation to the MELD score Table (7): HCV recurrence in relation to the MELD score Table (8): HCV recurrence in relation to CMV IgG Table (10): HCV recurrence in relation to CMV IgG Table (10): HCV recurrence in relation to pre transplant viremia titre Table (11): HCV recurrence in relation to pre transplant viremia level Table (13): HCV recurrence in relation to pre transplant viremia level Table (14): HCV recurrence in relation to pre transplant viremia level Table (15): Relation between HCV recurrence and HBc Ab total HCV recurrence in relation to pulse steroid Table (16): HCV recurrence in relation to to pulse steroid Table (17): HCV recurrence in relation to tacrolimus Table (18): HCV recurrence in relation to donor age HCV recurrence in relation to donor age Table (20): HCV recurrence in relation to donor sex Table (21): HCV recurrence in relation to recurrent HCV Table (23): Type of donor graft in relation to recurrent HCV Relation between GRWR (mean) and HCV recurrence Table (26): HCV recurrence in relation to recipient total hospital stay HCV recurrence in relation to INF+Ribavirin therapy Table (27): Time at which HCV recurrence was diagnosed		
Table (2): Demographic characteristics of the Donor Table (3): HCV recurrence (n=74) Table (4): HCV recurrence in the relation to the recipient sex Table (5): HCV recurrence in the relation to recipient age Table (6): HCV recurrence in relation to the MELD score Table (7): HCV recurrence in relation to the MELD score Table (8): HCV recurrence in relation to Child's score Table (9): HCV recurrence in relation to CMV lgG Table (10): HCV recurrence in relation to DMV lgG Table (11): HCV recurrence in relation to pre transplant viremia titre Table (12): HCV recurrence in relation to pre transplant viremia level Table (13): HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant and post transplant viremia titre Table (15): Relation between HCV recurrence and HBc Ab total Table (16): HCV recurrence in relation to pulse steroid Table (17): HCV recurrence in relation to tacrolimus HCV recurrence in relation to tacrolimus Table (18): HCV recurrence in relation to donor age HCV recurrence in relation to donor age HCV recurrence in relation to donor age Table (20): HCV recurrence in relation to of precurrent HCV Table (21): Type of donor graft in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Relation between GRWR and HCV recurrence Relation between GRWR and HCV recurrence Relation between estimated graft weight(g) and HCV recurrence Table (25): Relation between estimated graft weight(g) and HCV recurrence Table (26): HCV recurrence in relation to recipient total hospital stay HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed		
Table (3): HCV recurrence (n=74) Table (4): HCV recurrence in the relation to the recipient sex Table (5): HCV recurrence in the relation to recipient age Table (6): HCV recurrence in relation to the MELD score Table (7): HCV recurrence in relation to the MELD score Table (8): HCV recurrence in relation to Child's score Table (9): HCV recurrence in relation to CMV IgG Table (10): HCV recurrence in relation to CMV IgM Table (11): HCV recurrence in relation to pre transplant viremia titre Table (12): HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant and post transplant viremia titre Table (13): Relation between HCV recurrence and HBc Ab total HCV recurrence in relation to pulse steroid HCV recurrence in relation to tacrolimus HCV recurrence in relation to tacrolimus HCV recurrence in relation to tacrolimus toxicity Table (18): HCV recurrence in relation to donor age HCV recurrence in relation to donor age HCV recurrence in relation to donor sex Table (20): HCV recurrence in relation to recurrent HCV Table (22): Type of donor graft in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Relation between GRWR and HCV recurrence Relation between estimated graft weight(g) and HCV recurrence Table (25): Relation between in relation to recipient total hospital stay HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed	1 ' '	
Table (4): HCV recurrence in the relation to the recipient sex Table (5): HCV recurrence in the relation to recipient age Table (6): HCV recurrence in relation to the MELD score Table (7): HCV recurrence in relation to the MELD score Table (8): HCV recurrence in relation to Child's score Table (9): HCV recurrence in relation to CMV IgG Table (10): HCV recurrence in relation to CMV IgM Table (11): HCV recurrence in relation to pre transplant viremia titre Table (12): HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant and post transplant viremia titre Table (13): Relation between HCV recurrence and HBc Ab total HCV recurrence in relation to pulse steroid Table (16): HCV recurrence in relation to tacrolimus Table (17): HCV recurrence in comparison to tacrolimus Table (19): HCV recurrence in relation cyclosporine HCV recurrence in relation to donor age HCV recurrence in relation to donor age Table (20): HCV recurrence in relation to recurrent HCV Table (21): Type of donor graft in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Table (24): Relation between estimated graft weight(g) and HCV recurrence Table (25): Relation between estimated graft weight(g) and HCV recurrence Table (26): HCV recurrence in relation to INF+Ribavirin therapy Table (27): Time at which HCV recurrence was diagnosed	' '	
Table (5): HCV recurrence in the relation to recipient age Table (6): HCV recurrence in relation to the MELD score Table (7): HCV recurrence in relation to the MELD score Table (8): HCV recurrence in relation to Child's score Table (9): HCV recurrence in relation to CMV IgG Table (10): HCV recurrence in relation to CMV IgM Table (11): HCV recurrence in relation to pre transplant viremia titre Table (12): HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant and post transplant viremia titre Table (13): Relation between HCV recurrence and HBc Ab total HCV recurrence in relation to pulse steroid HCV recurrence in relation to tacrolimus Table (17): HCV recurrence in comparison to tacrolimus toxicity Table (18): HCV recurrence in relation cyclosporine Table (20): HCV recurrence in relation to donor age Table (21): HCV recurrence in relation to donor sex Table (22): Type of donor graft in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Table (24): Relation between GRWR and HCV recurrence Relation between GRWR and HCV recurrence Relation between estimated graft weight(g) and HCV recurrence HCV recurrence in relation to INF+Ribavirin therapy Table (27): Time at which HCV recurrence was diagnosed	, ,	
Table (6): HCV recurrence in relation to the MELD score Table (7): HCV recurrence in relation to the MELD score Table (8): HCV recurrence in relation to Child's score Table (9): HCV recurrence in relation to CMV IgG Table (10): HCV recurrence in relation to CMV IgM Table (11): HCV recurrence in relation to pre transplant viremia titre Table (12): HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant and post transplant viremia titre Table (13): Relation between HCV recurrence and HBc Ab total Table (15): Relation between HCV recurrence and HBc Ab total Table (16): HCV recurrence in relation to pulse steroid Table (17): HCV recurrence in relation to tacrolimus HCV recurrence in comparison to tacrolimus toxicity Table (18): HCV recurrence in relation to donor age Table (20): HCV recurrence in relation to donor age Table (21): HCV recurrence in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Table (24): Relation between GRWR and HCV recurrence Relation between estimated graft weight(g) and HCV recurrence Table (26): HCV recurrence in relation to recipient total hospital stay Table (27): HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed		
Table (7): HCV recurrence in relation to the MELD score Table (8): HCV recurrence in relation to Child's score Table (9): HCV recurrence in relation to CMV IgG Table (10): HCV recurrence in relation to CMV IgM Table (11): HCV recurrence in relation to pre transplant viremia titre Table (12): HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant and post transplant viremia titre Table (15): Relation between HCV recurrence and HBc Ab total HCV recurrence in relation to pulse steroid HCV recurrence in relation to tacrolimus HCV recurrence in comparison to tacrolimus toxicity HCV recurrence in relation cyclosporine HCV recurrence in relation to donor age HCV recurrence in relation to donor sex Table (21): HCV recurrence in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Relation between GRWR and HCV recurrence Relation between estimated graft weight(g) and HCV recurrence HCV recurrence in relation to recipient total hospital stay HCV recurrence in relation to INF+Ribavirin therapy Table (27): Time at which HCV recurrence was diagnosed		
Table (8): HCV recurrence in relation to Child's score Table (9): HCV recurrence in relation to CMV IgG Table (10): HCV recurrence in relation to CMV IgM Table (11): HCV recurrence in relation to pre transplant viremia titre Table (12): HCV recurrence in relation to pre transplant viremia level Table (13): HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant and post transplant viremia titre Table (15): Relation between HCV recurrence and HBc Ab total HCV recurrence in relation to pulse steroid HCV recurrence in relation to tacrolimus HCV recurrence in comparison to tacrolimus toxicity HCV recurrence in relation cyclosporine HCV recurrence in relation to donor age HCV recurrence in relation to donor sex Table (20): HCV recurrence in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Relation between GRWR and HCV recurrence Relation between GRWR and HCV recurrence HCV recurrence in relation to recipient total hospital stay HCV recurrence in relation to INF+Ribavirin therapy Table (27): Time at which HCV recurrence was diagnosed		
Table (9): HCV recurrence in relation to CMV IgG Table (10): HCV recurrence in relation to CMV IgM Table (11): HCV recurrence in relation to pre transplant viremia titre HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant and post transplant viremia titre Relation between HCV recurrence and HBc Ab total HCV recurrence in relation to pulse steroid HCV recurrence in relation to tacrolimus HCV recurrence in comparison to tacrolimus toxicity HCV recurrence in relation cyclosporine HCV recurrence in relation to donor age HCV recurrence in relation to donor age Table (21): HCV recurrence in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Table (24): Relation between GRWR and HCV recurrence HCV recurrence in relation to recipient total hospital stay HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed	, ,	
Table (10): HCV recurrence in relation to CMV IgM Table (11): HCV recurrence in relation to pre transplant viremia titre Table (12): HCV recurrence in relation to pre transplant viremia level Table (13): HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant and post transplant viremia titre Table (14): Relation between HCV recurrence and HBc Ab total HCV recurrence in relation to pulse steroid Table (16): HCV recurrence in relation to tacrolimus Table (18): HCV recurrence in comparison to tacrolimus toxicity Table (19): HCV recurrence in relation cyclosporine Table (20): HCV recurrence in relation to donor age Table (21): HCV recurrence in relation to donor sex Table (22): Type of donor graft in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Table (25): Relation between estimated graft weight(g) and HCV recurrence Table (26): HCV recurrence in relation to recipient total hospital stay Table (27): HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed		
Table (11): HCV recurrence in relation to pre transplant viremia titre Table (12): HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant and post transplant viremia titre Table (15): Relation between HCV recurrence and HBc Ab total HCV recurrence in relation to pulse steroid HCV recurrence in relation to tacrolimus HCV recurrence in comparison to tacrolimus toxicity HCV recurrence in relation cyclosporine HCV recurrence in relation to donor age HCV recurrence in relation to donor sex Table (21): HCV recurrence in relation to recurrent HCV Table (22): Type of donor graft in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Table (25): Relation between estimated graft weight(g) and HCV recurrence HCV recurrence in relation to recipient total hospital stay HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed		
Table (12): HCV recurrence in relation to pre transplant viremia level Table (13): HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant and post transplant viremia titre Table (15): Relation between HCV recurrence and HBc Ab total Table (16): HCV recurrence in relation to pulse steroid Table (17): HCV recurrence in relation to tacrolimus Table (18): HCV recurrence in comparison to tacrolimus toxicity HCV recurrence in relation cyclosporine Table (20): HCV recurrence in relation to donor age Table (21): HCV recurrence in relation to recurrent HCV Table (22): Type of donor graft in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Table (24): Relation between GRWR and HCV recurrence Table (25): Relation between estimated graft weight(g) and HCV recurrence Table (26): HCV recurrence in relation to recipient total hospital stay Table (27): HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed		
Table (13): HCV recurrence in relation to pre transplant viremia level HCV recurrence in relation to pre transplant and post transplant viremia titre Relation between HCV recurrence and HBc Ab total HCV recurrence in relation to pulse steroid HCV recurrence in relation to tacrolimus HCV recurrence in comparison to tacrolimus toxicity HCV recurrence in relation cyclosporine HCV recurrence in relation to donor age HCV recurrence in relation to donor sex Table (20): HCV recurrence in relation to recurrent HCV Table (22): Type of donor graft in relation to recurrent HCV Relation between GRWR (mean) and HCV recurrence Relation between GRWR and HCV recurrence Relation between estimated graft weight(g) and HCV recurrence HCV recurrence in relation to recipient total hospital stay Table (27): HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed		
Table (14): HCV recurrence in relation to pre transplant and post transplant viremia titre Table (15): Relation between HCV recurrence and HBc Ab total HCV recurrence in relation to pulse steroid HCV recurrence in relation to tacrolimus HCV recurrence in comparison to tacrolimus toxicity HCV recurrence in relation cyclosporine HCV recurrence in relation to donor age HCV recurrence in relation to donor sex Table (21): HCV recurrence in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Table (24): Relation between estimated graft weight(g) and HCV recurrence HCV recurrence in relation to recipient total hospital stay Table (27): HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed		
Table (15): Relation between HCV recurrence and HBc Ab total Table (16): HCV recurrence in relation to pulse steroid Table (17): HCV recurrence in relation to tacrolimus Table (18): HCV recurrence in comparison to tacrolimus toxicity Table (19): HCV recurrence in relation cyclosporine Table (20): HCV recurrence in relation to donor age Table (21): HCV recurrence in relation to donor sex Table (22): Type of donor graft in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Table (24): Relation between GRWR and HCV recurrence Table (25): Relation between estimated graft weight(g) and HCV recurrence Table (26): HCV recurrence in relation to recipient total hospital stay Table (27): HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed	1 ' '	HCV recurrence in relation to pre transplant and post transplant viremia
Table (16): HCV recurrence in relation to pulse steroid Table (17): HCV recurrence in relation to tacrolimus Table (18): HCV recurrence in comparison to tacrolimus toxicity Table (19): HCV recurrence in relation cyclosporine Table (20): HCV recurrence in relation to donor age Table (21): HCV recurrence in relation to donor sex Table (22): Type of donor graft in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Table (24): Relation between GRWR and HCV recurrence Table (25): Relation between estimated graft weight(g) and HCV recurrence Table (26): HCV recurrence in relation to recipient total hospital stay Table (27): HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed	12.00	
Table (16): HCV recurrence in relation to pulse steroid Table (17): HCV recurrence in relation to tacrolimus Table (18): HCV recurrence in comparison to tacrolimus toxicity Table (19): HCV recurrence in relation cyclosporine Table (20): HCV recurrence in relation to donor age Table (21): HCV recurrence in relation to donor sex Table (22): Type of donor graft in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Table (24): Relation between GRWR and HCV recurrence Table (25): Relation between estimated graft weight(g) and HCV recurrence Table (26): HCV recurrence in relation to recipient total hospital stay Table (27): HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed	Table (15):	Relation between HCV recurrence and HBc Ab total
Table (17): HCV recurrence in relation to tacrolimus Table (18): HCV recurrence in comparison to tacrolimus toxicity Table (19): HCV recurrence in relation cyclosporine Table (20): HCV recurrence in relation to donor age Table (21): HCV recurrence in relation to donor sex Table (22): Type of donor graft in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Table (24): Relation between GRWR and HCV recurrence Table (25): Relation between estimated graft weight(g) and HCV recurrence Table (26): HCV recurrence in relation to recipient total hospital stay Table (27): HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed		
Table (18): HCV recurrence in comparison to tacrolimus toxicity Table (19): HCV recurrence in relation cyclosporine Table (20): HCV recurrence in relation to donor age Table (21): HCV recurrence in relation to donor sex Table (22): Type of donor graft in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Table (24): Relation between GRWR and HCV recurrence Table (25): Relation between estimated graft weight(g) and HCV recurrence HCV recurrence in relation to recipient total hospital stay Table (27): HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed		HCV recurrence in relation to tacrolimus
Table (19): HCV recurrence in relation cyclosporine Table (20): HCV recurrence in relation to donor age Table (21): HCV recurrence in relation to donor sex Table (22): Type of donor graft in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Table (24): Relation between GRWR and HCV recurrence Table (25): Relation between estimated graft weight(g) and HCV recurrence Table (26): HCV recurrence in relation to recipient total hospital stay Table (27): HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed	, ,	HCV recurrence in comparison to tacrolimus toxicity
Table (20): HCV recurrence in relation to donor age Table (21): HCV recurrence in relation to donor sex Table (22): Type of donor graft in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Table (24): Relation between GRWR and HCV recurrence Table (25): Relation between estimated graft weight(g) and HCV recurrence Table (26): HCV recurrence in relation to recipient total hospital stay Table (27): HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed		
Table (21): HCV recurrence in relation to donor sex Table (22): Type of donor graft in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Table (24): Relation between GRWR and HCV recurrence Table (25): Relation between estimated graft weight(g) and HCV recurrence Table (26): HCV recurrence in relation to recipient total hospital stay Table (27): HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed		
Table (22): Type of donor graft in relation to recurrent HCV Table (23): Relation between GRWR (mean) and HCV recurrence Table (24): Relation between GRWR and HCV recurrence Table (25): Relation between estimated graft weight(g) and HCV recurrence HCV recurrence in relation to recipient total hospital stay Table (27): HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed	Table (21):	HCV recurrence in relation to donor sex
Table (24): Relation between GRWR and HCV recurrence Table (25): Relation between estimated graft weight(g) and HCV recurrence Table (26): HCV recurrence in relation to recipient total hospital stay HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed		Type of donor graft in relation to recurrent HCV
Table (25): Relation between estimated graft weight(g) and HCV recurrence HCV recurrence in relation to recipient total hospital stay HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed	Table (23):	Relation between GRWR (mean) and HCV recurrence
Table (26): HCV recurrence in relation to recipient total hospital stay Table (27): HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed	Table (24):	Relation between GRWR and HCV recurrence
Table (26): HCV recurrence in relation to recipient total hospital stay Table (27): HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed		
Table (27): HCV recurrence in relation to INF+Ribavirin therapy Table (28): Time at which HCV recurrence was diagnosed	Table (26):	
	Table (27):	
Table (29): Time interval at which HCV recurrence was diagnosed	Table (28):	Time at which HCV recurrence was diagnosed
	Table (29):	Time interval at which HCV recurrence was diagnosed